Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DB-1421
- Development stage
- Preclinical
- Lead developer
- Duality Biotherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DB-1421 is a preclinical-stage bispecific antibody-drug conjugate (ADC) developed by DualityBio for the treatment of solid tumors. Built on the proprietary DIBAC (Duality Innovative Bispecific Antibody Conjugate) platform, DB-1421 is designed to simultaneously target two different tumor-associated antigens or epitopes. This dual-targeting approach aims to enhance tumor specificity, promote ADC internalization, and overcome potential resistance mechanisms associated with single-target therapies. While the specific molecular targets and payload remain undisclosed, the drug is intended to deliver a potent cytotoxic payload directly to cancer cells while minimizing off-target effects.
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)MUC1 (Mucin-1 Antigen)TOP (DNA topoisomerases)
Beyond the preview
Go deeper on DB-1421.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DB-1421.